Literature DB >> 7908906

D-type cyclin-binding regions of proliferating cell nuclear antigen.

S Matsuoka1, M Yamaguchi, A Matsukage.   

Abstract

Proliferating cell nuclear antigen (PCNA) is an auxiliary protein for DNA polymerase delta and is required for both DNA replication and DNA repair. PCNA forms complexes with D-type cyclins, candidate G1 cyclins in mammalian cells. To better understand the functions of the complexes, we examined interactions between PCNA and D-type cyclins, using in vitro-translated mouse PCNA and mouse cyclin D1 or D3 fused to glutathione S-transferase (GST). Analysis of a set of deletion mutants of PCNA revealed that either the N-terminal (residues 2-64) or the C-terminal (residues 197-228) region is necessary for association with D-type cyclins. The cyclin binding of the chimeric protein of the N-terminal (residues 1-68) or the C-terminal (residues 195-261) region of PCNA and rat DNA polymerase beta which does not bind to the cyclins by itself supports this notion. The purified recombinant mouse PCNA expressed in Escherichia coli bound to the D-type cyclin-GST fusion proteins, thereby suggesting that PCNA binds directly to D-type cyclins, without the requirement of other cellular factors. This is apparently the first report on the structure-function relationship of PCNA which may link DNA replication and DNA repair with cell cycle control.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7908906

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

Review 1.  Molecular interaction map of the mammalian cell cycle control and DNA repair systems.

Authors:  K W Kohn
Journal:  Mol Biol Cell       Date:  1999-08       Impact factor: 4.138

2.  Characterization of dRFX2, a novel RFX family protein in Drosophila.

Authors:  Kyoko Otsuki; Yuko Hayashi; Masaki Kato; Hideki Yoshida; Masamitsu Yamaguchi
Journal:  Nucleic Acids Res       Date:  2004-10-19       Impact factor: 16.971

3.  A direct interaction between a DNA-tracking protein and a promoter recognition protein: implications for searching DNA sequence.

Authors:  R L Tinker-Kulberg; T J Fu; E P Geiduschek; G A Kassavetis
Journal:  EMBO J       Date:  1996-09-16       Impact factor: 11.598

4.  Single point mutations located outside the inter-monomer domains abolish trimerization of Schizosaccharomyces pombe PCNA.

Authors:  K Piard; G Baldacci; I Tratner
Journal:  Nucleic Acids Res       Date:  1998-06-01       Impact factor: 16.971

5.  The Janus face of p21.

Authors:  Konstantinos Evangelou; Panagiotis Galanos; Vassilis G Gorgoulis
Journal:  Mol Cell Oncol       Date:  2016-07-29

6.  Structural and biochemical studies of human proliferating cell nuclear antigen complexes provide a rationale for cyclin association and inhibitor design.

Authors:  George Kontopidis; Su-Ying Wu; Daniella I Zheleva; Paul Taylor; Campbell McInnes; David P Lane; Peter M Fischer; Malcolm D Walkinshaw
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-28       Impact factor: 11.205

7.  GCNF-dependent activation of cyclin D1 expression via repression of Mir302a during ESC differentiation.

Authors:  Hongran Wang; Xiaohong Wang; Trevor K Archer; Thomas P Zwaka; Austin J Cooney
Journal:  Stem Cells       Date:  2014-06       Impact factor: 6.277

Review 8.  Proteomic identification of a direct role for cyclin d1 in DNA damage repair.

Authors:  Siwanon Jirawatnotai; Yiduo Hu; David M Livingston; Piotr Sicinski
Journal:  Cancer Res       Date:  2012-08-22       Impact factor: 12.701

9.  Phosphorylation of cyclin D1 regulated by ATM or ATR controls cell cycle progression.

Authors:  Masahiro Hitomi; Ke Yang; Andrew W Stacey; Dennis W Stacey
Journal:  Mol Cell Biol       Date:  2008-07-07       Impact factor: 4.272

10.  Apoptosis and PCNA expression induced by prolactin in structural involution of the rat corpus luteum.

Authors:  T Kiya; T Endo; T Goto; H Yamamoto; E Ito; R Kudo; H R Behrman
Journal:  J Endocrinol Invest       Date:  1998-05       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.